Dharmarajan K, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in older adults. Heart Fail Clin. 2007;3:381–7.
Heart Disease and Stroke Statistics—2021 Update | Circulation. https://doi.org/10.1161/CIR.0000000000000950. Accessed 5 Feb 2022.
Heart failure before age 65: how does it happen? In: Clevel. Clin. 2017. https://health.clevelandclinic.org/heart-failure-before-age-65-how-does-it-happen/. Accessed 10 Jan 2022.
Statistical Brief #66. https://www.hcup-us.ahrq.gov/reports/statbriefs/sb66.jsp. Accessed 5 Feb 2022.
Dharmarajan K. Comprehensive Strategies to reduce readmissions in older patients with cardiovascular disease. Can J Cardiol. 2016;32:1306–14.
Dharmarajan K, Hsieh AF, Kulkarni VT, et al. Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study. BMJ. 2015;350:h411.
Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124:136–43.
Screever EM, Meijers WC, van Veldhuisen DJ, de Boer RA. New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations. Expert Opin Pharmacother. 2017;18:645–55.
Gorodeski EZ, Goyal P, Hummel SL, Krishnaswami A, Goodlin SJ, Hart LL, Forman DE, Wenger NK, Kirkpatrick JN, Alexander KP. Domain management approach to heart failure in the geriatric patient: present and future. J Am Coll Cardiol. 2018;71:1921–36.
Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation: making it safe and sound. London: King’s Fund; 2013.
Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176:473–82.
Beezer J, Al Hatrushi M, Husband A, Kurdi A, Forsyth P. Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Fail Rev. 2022;27(2):465–92. https://doi.org/10.1007/s10741-021-10135-4. Erratum in: Heart Fail Rev. 2021 Jul 31.
Krishnaswami A, Steinman MA, Goyal P, et al. Deprescribing in older adults with cardiovascular disease. J Am Coll Cardiol. 2019;73:2584–95.
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230.
Wu Y, Zhu W, He X, et al. Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial. Br J Gen Pract. 2020;71:e62–70.
Unlu O, Levitan EB, Reshetnyak E, et al. Polypharmacy in older adults hospitalized for heart failure. Circ Heart Fail. 2020;13:e006977.
Navid P, Nguyen L, Jaber D, et al. Attitudes toward deprescribing among adults with heart failure with preserved ejection fraction. J Am Geriatr Soc. 2021;69:1948–55.
Goyal P, Mangal S, Krishnaswami A, Rich MW. Polypharmacy in heart failure: progress but also problem. Am J Med. 2021;134:1071–3.
Rao VN, Fudim M, Savarese G, Butler J. Polypharmacy in Heart failure with reduced ejection fraction: progress, not problem. Am J Med. 2021;134:1068–70.
Steinman MA. Polypharmacy—Time to Get Beyond Numbers. JAMA Intern Med. 2016;176:482–3.
Wise J. Polypharmacy: a necessary evil. BMJ. 2013;347:f7033.
Gurwitz JH. Polypharmacy: a new paradigm for quality drug therapy in the elderly? Arch Intern Med. 2004;164:1957–9.
Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591–602. https://doi.org/10.1038/nrcardio.2017.65.
Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226–33.
Marcum ZA, Amuan ME, Hanlon JT, Aspinall SL, Handler SM, Ruby CM, Pugh MJV. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc. 2012;60:34–41.
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65.
Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010;19:901–10.
Akazawa M, Imai H, Igarashi A, Tsutani K. Potentially inappropriate medication use in elderly Japanese patients. Am J Geriatr Pharmacother. 2010;8:146–60.
Chang TI, Park H, Kim DW, Jeon EK, Rhee CM, Kalantar-Zadeh K, Kang EW, Kang S-W, Han SH. Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study. Sci Rep. 2020;10:18964.
Crentsil V, Ricks MO, Xue Q-L, Fried LP. A pharmacoepidemiologic study of community-dwelling, disabled older women: Factors associated with medication use. Am J Geriatr Pharmacother. 2010;8:215–24.
Jyrkkä J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011;20:514–22.
Magaziner J, Cadigan DA. Community resources and mental health of older women living alone. J Aging Health. 1989;1:35–49.
Zhou T, Liu P, Dhruva SS, Shah ND, Ramachandran R, Berg KM, Ross JS. Assessment of hypothetical out-of-pocket costs of guideline-recommended medications for the treatment of older adults with multiple chronic conditions, 2009 and 2019. JAMA Intern Med. 2022. https://doi.org/10.1001/jamainternmed.2021.7457.
Rochon PA, Gurwitz JH. The prescribing cascade revisited. Lancet. 2017;389:1778–80.
Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14.
Verdiani V, Panigada G, Fortini A, Masotti L, Meini S, Biagi P, Group for the SS. The heart failure in Internal Medicine in Tuscany: the SMIT Study. Ital J Med. 2015;9:349–55.
Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US Emergency Department Visits for Outpatient Adverse Drug Events, 2013–2014. JAMA. 2016;316:2115–25.
Page RL, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J. Drugs That May Cause or Exacerbate Heart Failure. Circulation. 2016;134:e32–69.
Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30–41.
Liu Q, Schwartz JB, Slattum PW, Lau SWJ, Guinn D, Madabushi R, Burckart G, Califf R, Cerreta F, Cho C, Cook J, Gamerman J, Goldsmith P, van der Graaf PH, Gurwitz JH, Haertter S, Hilmer S, Huang SM, Inouye SK, et al. Roadmap to 2030 for drug evaluation in older adults. Clin Pharmacol Ther. 2021. https://doi.org/10.1002/cpt.2452.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077.
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E, PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380:539–48.
Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–20.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008.
Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–24.
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–61.
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35.
Investigators SOLVD, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302. https://doi.org/10.1056/NEJM199108013250501.
Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Östergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–6.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.
Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERITHF). Lancet. 1999;353(9169):2001–7.
Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med. 2011;364:11–21.
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–85.
Reeve E, Thompson W, Farrell B. Deprescribing: A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med. 2017;38:3–11.
Vardeny O, Claggett B, Anand I, et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2020;75:910–910.
Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter 2 inhibitors and the risk of severe urinary tract infections. Ann Intern Med. 2019;171:248–56.
Chaplin S. SGLT2 inhibitors and risk of genitourinary infections. Prescriber. 2016;27:26–30.
Patorno E, Gopalakrishnan C, Kim D. Monitoring the effectiveness and safety of ARNI vs. angiotensin receptor blocker by frailty status. Innov Aging. 2021;5:209.
Gatti M, Antonazzo IC, Diemberger I, De Ponti F, Raschi E. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur J Prev Cardiol. 2021;28(9):983–9. https://doi.org/10.1177/2047487320915663.
Nanna MG, Chen ST, Nelson AJ, Navar AM, Peterson ED. Representation of older adults in cardiovascular disease trials since the inclusion across the lifespan policy. JAMA Intern Med. 2020;180:1531–3.
Seo W-W, Park JJ, Park HA, et al. Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a cohort study. BMJ Open. 2020;10:e030514.
Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P, Anand IS, Lam CSP, Voors AA. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2022;10(2):73–84. https://doi.org/10.1016/j.jchf.2021.09.004.
Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396:121–8.
Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393:61–73.
Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2018;72:351–66.
van Riet EES, Hoes AW, Wagenaar KP, Limburg A, Landman MAJ, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18:242–52.
Seto H, Ishimaru N, Ohnishi J, Kanzawa Y, Nakajima T, Shimokawa T, Imanaka Y, Kinami S. Multidisciplinary Team deprescribing intervention for polypharmacy in elderly orthopedic inpatients: a propensity score-matched analysis of a retrospective cohort study. Intern Med Tokyo Jpn. 2022. https://doi.org/10.2169/internalmedicine.8929-21.
Attar D, Lekura J, Kalus JS, Al-Darzi W, Williams CT, Grafton GF. Impact of a pharmacist-led heart failure clinic on guideline-directed medical therapy. J Card Fail. 2020;26:S129.
Shah SP, Dixit NM, Mendoza K, Entabi R, Meymandi S, Balady-Bouziane N, Chan P. Integration of clinical pharmacists into a heart failure clinic within a safety-net hospital. J Am Pharm Assoc. 2021. https://doi.org/10.1016/j.japh.2021.11.012.
Tobias DE. Start Low and Go Slow. Hosp Pharm. 2003;38:634–6.
Tinetti ME, Kumar C. The patient who falls: “It’s always a trade-off.” JAMA. 2010;303:258–66.
Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive “vital signs” measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15:1021–7.
Marcantonio ER. Delirium in Hospitalized Older Adults. N Engl J Med. 2017;377:1456–66.
Storey JE, Rowland JTJ, Basic D, Conforti DA, Dickson HG. The Rowland Universal Dementia Assessment Scale (RUDAS): a multicultural cognitive assessment scale. Int Psychogeriatr. 2004;16:13–31.
Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80:1254–68.
Rossello X, Pocock SJ, Julian DG. Long-Term Use of Cardiovascular Drugs. J Am Coll Cardiol. 2015;66:1273–85.
Bloomfield HE, Greer N, Linsky AM, Bolduc J, Naidl T, Vardeny O, MacDonald R, McKenzie L, Wilt TJ. Deprescribing for community-dwelling older adults: a systematic review and meta-analysis. J Gen Intern Med. 2020;35:3323–32.
Mair A, Wilson M, Dreischulte T. Addressing the challenge of polypharmacy. Annu Rev Pharmacol Toxicol. 2020;60:661–81.
McDonald EG, Wu PE, Rashidi B, et al. The MedSafer Study—Electronic decision support for deprescribing in hospitalized older adults: a cluster randomized clinical trial. JAMA Intern Med. 2022. https://doi.org/10.1001/jamainternmed.2021.7429.
Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial. JAMA. 2018;320:1889–98.
Goyal P, Anderson TS, Bernacki GM, et al. Physician perspectives on deprescribing cardiovascular medications for older adults. J Am Geriatr Soc. 2020;68:78–86.
Curtin D, Gallagher PF, O’Mahony D. Explicit criteria as clinical tools to minimize inappropriate medication use and its consequences. Ther Adv Drug Saf. 2019;10:2042098619829431.
Deprescribing.org - Optimizing Medication Use. In: Deprescribing.org. https://deprescribing.org/. Accessed 18 Nov 2021.
MedStopper. https://medstopper.com/. Accessed 18 Nov 2021.
Lee SJ, Leipzig RM, Walter LC. “When Will it Help?” Incorporating Lagtime to Benefit into Prevention Decisions for Older Adults. JAMA. 2013;310:2609–10.
O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8.
Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175:827–34.
Rankin A, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;9(9):CD008165. https://doi.org/10.1002/14651858.CD008165.pub4.
Tarn D, Schwartz J. Polypharmacy: A Five-Step Call to Action for Family Physicians. Fam Med. 2020;52:699–701.
Ghazi L, Yamamoto Y, Riello RJ, et al. Electronic Alerts to improve heart failure therapy in outpatient practice: a cluster randomized trial. J Am Coll Cardiol. 2022. https://doi.org/10.1016/j.jacc.2022.03.338.
Chow CK, Atkins ER, Hillis GS, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398:1043–52.
Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseasesimplications for pay for performance. JAMA. 2005;294:716–24.